SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough
暂无分享,去创建一个
William L. Hamilton | S. Bhatt | S. Flaxman | Raju Vaishya | Swapnil Mishra | T. Mellan | C. Whittaker | Jie Zhou | L. James | Ravindra K. Gupta | P. Mlcochova | R. Pandey | S. Singh | T. Peacock | Jonathan C. Brown | W. Barclay | D. Corti | Kei Sato | N. Goel | C. Wattal | L. Piccoli | Kalaiarasan Ponnusamy | T. Irie | D. Pinto | Meenakshi Agarwal | B. Meng | D. Caputo | Anna Albecka | M. S. Dhar | J. Bassi | D. Collier | V. Radhakrishnan | Meena Datta | P. Rakshit | P. Chattopadhyay | S. Sengupta | P. Devi | C. Saliba | S. Kemp | Anurag Agrawal | I. Yoshida | G. Papa | A. Abdullahi | I. Ferreira | R. Datir | Robin Marwal | O. Charles | A. Satwik | Antranik Mavousian | J. Lee | Chiara Silacci-Fegni | Niluka Goonawardne
[1] S. Munro,et al. Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation , 2021, Nature Communications.
[2] Frances E. Muldoon,et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.
[3] S. Jagannath,et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma , 2021, Cancer Cell.
[4] M. Landray,et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.
[5] J. Zahradník,et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity , 2021, Cell Host & Microbe.
[6] A. Sigal,et al. SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization , 2021, bioRxiv.
[7] S. Whelan,et al. SARS-CoV-2 Spreads through Cell-to-Cell Transmission , 2021, bioRxiv.
[8] William T. Harvey,et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 , 2021, Cell Reports.
[9] F. Rey,et al. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals , 2021, bioRxiv.
[10] N. Andrews,et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant , 2021, medRxiv.
[11] H. Jäck,et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination , 2021, bioRxiv.
[12] S. Singh,et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India , 2021, bioRxiv.
[13] M. Giacca,et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets , 2021, Nature Microbiology.
[14] S. Panda,et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees , 2021, bioRxiv.
[15] A. Huppert,et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals , 2021, Nature Medicine.
[16] M. Giacca,et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia , 2021, Nature.
[17] J. Zahradník,et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity , 2021, bioRxiv.
[18] A. Telenti,et al. Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies , 2021, bioRxiv.
[19] A. Telenti,et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429 , 2021, bioRxiv.
[20] Graham W. Taylor,et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.
[21] M. Beltramello,et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, Cell.
[22] R. Andino,et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation , 2021, medRxiv.
[23] S. Neil,et al. The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2 , 2021, Journal of Virology.
[24] D. Robertson,et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research , 2021, PLoS biology.
[25] Graham W. Taylor,et al. SARS-CoV-2 evolution during treatment of chronic infection , 2021, Nature.
[26] Vineet D. Menachery,et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis , 2021, Nature.
[27] William T. Harvey,et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies , 2021, medRxiv : the preprint server for health sciences.
[28] W. P. Duprex,et al. Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape , 2020, bioRxiv.
[29] Ho Min Kim,et al. Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2 , 2020, Cell Stem Cell.
[30] S. Munro,et al. Sequences in the cytoplasmic tail of SARS-CoV-2 spike facilitate syncytia formation , 2020, bioRxiv.
[31] A. Boon,et al. A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2 Growth in Cell Culture , 2020, mSphere.
[32] Steven F. Baker,et al. Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant , 2020, Cell Reports Medicine.
[33] S. Munro,et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion , 2020, bioRxiv.
[34] Sumit Sharma,et al. High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing , 2020, bioRxiv.
[35] Edward C. Holmes,et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.
[36] H. Mouquet,et al. Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.
[37] J. Skehel,et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects , 2020, Nature Structural & Molecular Biology.
[38] C. Rice,et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.
[39] Yan Liu,et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.
[40] Fumihiro Kato,et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.
[41] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[42] Olga Chernomor,et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.
[43] Trevor Bedford,et al. Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.
[44] David K. Smith,et al. ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data , 2017 .
[45] Y. Hata,et al. A new cell-based assay to evaluate myogenesis in mouse myoblast C2C12 cells. , 2015, Experimental cell research.
[46] Levente Csikor,et al. ESCAPE , 2014, The Complete Lives of Camp People.
[47] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.
[48] B. Verhasselt,et al. Quantification of Reverse Transcriptase Activity by Real-Time PCR as a Fast and Accurate Method for Titration of HIV, Lenti- and Retroviral Vectors , 2012, PloS one.
[49] Pradeep Kota,et al. Automated minimization of steric clashes in protein structures , 2011, Proteins.
[50] R. Joynt. Department , 1960, Neurology.
[51] OUP accepted manuscript , 2021, The Journal of Infectious Diseases.
[52] J. Luban. SARS-CoV-2 , 2020 .
[53] U. Kubitscheck,et al. KEY WORDS: , 2008 .